1. Dual Effect of the Broad Spectrum Kinase Inhibitor Midostaurin in Acute and Latent HIV-1 Infection.Garcia-Vidal, E., R. Badia, M. Pujantell, M. Castellvi, E. Felip, B. Clotet, E. Riveira-Munoz, E. Ballana, and J.A. Este. Antiviral Research, 2019. 168: p. 18-27. PMID[31077767].
[PubMed]. HIV_09_2019.
2. Molecular Docking, Design, Synthesis and Biological Evaluation of Novel 2,3-Aryl-thiazolidin-4-ones as Potent NNRTIs. Geronikaki, A., A. Petrou, V. Kartsev, P. Eleftheriou, R. Boga, B. Bartolo, E. Crespan, G. Franco, and G. Maga. SAR and QSAR in Environmental Research, 2019. 30(10): p. 697-714. PMID[31542957].
[PubMed]. HIV_09_2019.
3. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands to Optimize Hydrogen Bonding in the Substrate Envelope. Rusere, L.N., G.J. Lockbaum, S.K. Lee, M. Henes, K. Kosovrasti, E. Spielvogel, E.A. Nalivaika, R. Swanstrom, N.K. Yilmaz, C.A. Schiffer, and A. Ali. Journal of Medicinal Chemistry, 2019. 62(17): p. 8062-8079. PMID[31386368].
[PubMed]. HIV_09_2019.
4. Ramified Derivatives of 5-(Perylen-3-ylethynyl)uracil-1-acetic acid and Their Antiviral Properties.Sapozhnikova, K.A., N.A. Slesarchuk, A.A. Orlov, E.V. Khvatov, E.V. Radchenko, A.A. Chistov, A.V. Ustinov, V.A. Palyulin, L.I. Kozlovskaya, D.I. Osolodkin, V.A. Korshun, and V.A. Brylev. RSC Advances, 2019. 9(45): p. 26014-26023. ISI[000483541000008].
[WOS]. HIV_09_2019.
5. A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor. Tan, S., W. Li, Z. Li, Y. Li, J. Luo, L. Yu, J. Yang, M. Qiu, H. Cheng, W. Xu, S. Jiang, L. Lu, S. Liu, and W. Ma. Viruses, 2019. 11(9): e874. PMID[31540474].
[PubMed]. HIV_09_2019.
6. Quinolone Derivatives: Potential anti-HIV Agent-development and Application. Wang, R., K. Xu, and W.X. Shi. Archiv der Pharmazie, 2019. 352(9): e1900045. PMID[31274223].
[PubMed]. HIV_09_2019.
7. A Highly Potent Long-acting Small-molecule HIV-1 Capsid Inhibitor with Efficacy in a Humanized Mouse Model.Yant, S.R., A. Mulato, D. Hansen, W.C. Tse, A. Niedziela-Majka, J.R. Zhang, G.J. Stepan, D. Jin, M.H. Wong, J.M. Perreira, E. Singer, G.A. Papalia, E.Y. Hu, J. Zheng, B. Lu, S.D. Schroeder, K. Chou, S. Ahmadyar, A. Liclican, H. Yu, N. Novikov, E. Paoli, D. Gonik, R.R. Ram, M. Hung, W.M. McDougall, A.L. Brass, W.I. Sundquist, T. Cihlar, and J.O. Link. Nature Medicine, 2019. 25(9): p. 1377-1384. PMID[31501601].
[PubMed]. HIV_09_2019.
8. Synthesis and anti-HIV Activity of L-2',3'-Dideoxy-4'-selenonucleosides (L-4'-Se-ddNs). Yu, J., G. Kim, D.B. Jarhad, H.R. Kim, and L.S. Jeong. Archives of Pharmacal Research, 2019. 42(9): p. 780-789. PMID[31041687].
[PubMed]. HIV_09_2019.
Patent Citations
9. Compounds Useful in HIV Therapy.De la Rosa, M.A., J.F. Miller, D. Temelkoff, and E.J. Velthuisen. Patent. 2019. 2019-IB51799 2019171285: 77pp.
[Patent]. HIV_09_2019.
10. Preparation of Tricyclic Heterocycles as HIV Integrase Inhibitors for the Treatment and Prevention of AIDS.Embrey, M.W., T.J. Hartingh, M. Labroli, and I.T. Raheem. Patent. 2019. 2019-US17409 2019160783: 75pp.
[Patent]. HIV_09_2019.
11. Inhibitors of Neutral Sphingomyelinase 2(Nsmase2) for the Treatment of Human Immunodeficiency Virus Infection.Haughey, N., B. Slusher, and C. Rojas. Patent. 2019. 2019-US20258 2019169249: 117pp.
[Patent]. HIV_09_2019.
12. Fusion Proteins Comprising Soluble Human CD24 and Fc for Treating Acquired Immune Deficiency Syndrome (HIV/AIDS).Liu, Y., P. Zheng, L. Su, Y.-T. Zheng, and L. Zhang. Patent. 2019. 2019-US20712 2019173310: 68pp.
[Patent]. HIV_09_2019.
13. Vpx Protein as a Transgene Activator for Use in Gene Therapy or for Latent Virus Reactivation. Margottin-Goguet, F., L.G. Chougui, L. Etienne, and S. Munir-Matloob. Patent. 2019. 2019-EP56605 2019175415: 45pp.
[Patent]. HIV_09_2019.